CompletedPhase 3

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

127 participantsStarted 2009-01

Plain-language summary

The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive types).

Who can participate

Age range

1 Year – 11 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months of screening * Positive esophagogastroduodenoscopy * Signed informed consent * Female patients (if menstruating) must be practicing birth control Exclusion Criteria: * Patients with history of esophagitis * Patients who have milk protein allergy * Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days * Patients who have taken sucralate or any medication that affects gastrointestinal motility * Patients with H. pylori * Patients with lab values outside the normal age appropriate range * Patients who have participated in another trial within 30 days before screening * Patients with allergies to Proton Pump Inhibitors

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)

Timeframe: 12 weeks

The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)

Timeframe: 36 weeks

Trial details

NCT IDNCT00787891

SponsorJohnson & Johnson Pharmaceutical Research & Development, L.L.C.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-01

Results submitted2012-07-27

View on ClinicalTrials.gov More Gastroesophageal Reflux Disease (GERD) trials

Who can participate

Age range

1 Year – 11 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.